PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer

Launched by UNIVERSITY HOSPITAL, ESSEN · Mar 15, 2024

Keywords

ClinConnect Summary

The PROMISE PET Registry is a clinical trial aimed at understanding how a special type of imaging called PSMA PET can help predict outcomes for patients with prostate cancer. Researchers want to see if this imaging method provides better information about a patient’s cancer stage compared to traditional clinical assessments. By gathering data from patients who have undergone PSMA PET scans, the study hopes to improve how doctors can guide treatment decisions and plan future research.

To participate in this trial, you must be an adult man with confirmed prostate cancer who has had a PSMA PET scan for staging or restaging purposes. It's important that you have at least three years of follow-up health information available. However, if you have a specific type of prostate cancer called neuroendocrine cancer, or if you have another type of widespread cancer, you won’t be eligible. If you join the study, you can expect to contribute to valuable research that may help improve care for future prostate cancer patients.

Gender

MALE

Eligibility criteria

• Inclusion:
• • Adult patients with
• • biopsy/histo proven prostate cancer who
• • underwent PSMA PET (any type)
• • for staging or re-staging at any stage and who
• • have at least 3-year overall survival follow-up data available will be included consecutively.
• Exclusion:
• • Patients with neuroendocrine prostate cancer
• • Patients with metastasized or disseminated malignancy other than prostate cancer.